Literature DB >> 18929121

Astrocytes in glaucomatous optic neuropathy.

M Rosario Hernandez1, Haixi Miao, Thomas Lukas.   

Abstract

Glaucoma, the second most prevalent cause of blindness worldwide, is a degenerative disease characterized by loss of vision due to loss of retinal ganglion cells. There is no cure for glaucoma, but early intervention with drugs and/or surgery may slow or halt loss of vision. Increased intraocular pressure (IOP), age, and genetic background are the leading risk factors for glaucoma. Our laboratory and other investigators have provided evidence that astrocytes are the cells responsible for many pathological changes in the glaucomatous optic nerve head (ONH). Over several years, in vivo and in vitro techniques characterized the changes in quiescent astrocytes that lead to the reactive phenotype in glaucoma. Reactive astrocytes alter the homeostasis and integrity of the neural and connective tissues in the ONH of human and experimental glaucoma in monkeys. During the transition of quiescent astrocytes to the reactive phenotype altered astrocyte homeostatic functions such as cell-cell communication, migration, growth factor pathway activation, and responses to oxidative stress may impact pathological changes in POAG. Our data also suggests that the creation of a non-supportive environment for the survival of RGC axons through remodeling of the ONH by reactive astrocytes leads to progression of glaucomatous optic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929121     DOI: 10.1016/S0079-6123(08)01125-4

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  83 in total

1.  Proteomics analyses of human optic nerve head astrocytes following biomechanical strain.

Authors:  Ronan S Rogers; Moyez Dharsee; Suzanne Ackloo; Jeremy M Sivak; John G Flanagan
Journal:  Mol Cell Proteomics       Date:  2011-11-29       Impact factor: 5.911

Review 2.  A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2010-09-16       Impact factor: 3.467

3.  Isolation and characterization of human optic nerve head astrocytes and lamina cribrosa cells.

Authors:  Navita N Lopez; Abbot F Clark; Tara Tovar-Vidales
Journal:  Exp Eye Res       Date:  2020-06-06       Impact factor: 3.467

4.  Curcumin attenuates staurosporine-mediated death of retinal ganglion cells.

Authors:  Balabharathi Burugula; Bhagyalaxmi S Ganesh; Shravan K Chintala
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-16       Impact factor: 4.799

5.  Bioinformatics analysis of potential essential genes that response to the high intraocular pressure on astrocyte due to glaucoma.

Authors:  Yang Yang; Jing-Zhu Duan; Yu Di; Dong-Mei Gui; Dian-Wen Gao
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

6.  Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma.

Authors:  Dongwook Lee; Myoung Sup Shim; Keun-Young Kim; You Hyun Noh; Heemin Kim; Sang Yeop Kim; Robert N Weinreb; Won-Kyu Ju
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

Review 7.  Differential gene expression in glaucoma.

Authors:  Tatjana C Jakobs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

8.  The non-human primate experimental glaucoma model.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2015-06-09       Impact factor: 3.467

Review 9.  Astrocytes: biology and pathology.

Authors:  Michael V Sofroniew; Harry V Vinters
Journal:  Acta Neuropathol       Date:  2009-12-10       Impact factor: 17.088

10.  Functional and morphological effects of laser-induced ocular hypertension in retinas of adult albino Swiss mice.

Authors:  Manuel Salinas-Navarro; Luis Alarcón-Martínez; Francisco Javier Valiente-Soriano; Arturo Ortín-Martínez; Manuel Jiménez-López; Marcelino Avilés-Trigueros; María Paz Villegas-Pérez; Pedro de la Villa; Manuel Vidal-Sanz
Journal:  Mol Vis       Date:  2009-12-05       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.